Short Interest in Affimed (NASDAQ:AFMD) Declines By 14.9%

Affimed (NASDAQ:AFMD) saw a significant decline in short interest during the month of March. As of March 15th, there was short interest totalling 602,500 shares, a decline of 14.9% from the February 28th total of 708,100 shares. Approximately 4.6% of the company’s shares are sold short. Based on an average trading volume of 186,000 shares, the days-to-cover ratio is currently 3.2 days.

Hedge Funds Weigh In On Affimed

A number of large investors have recently bought and sold shares of the business. Northern Trust Corp purchased a new stake in shares of Affimed during the fourth quarter valued at $218,000. Intellectus Partners LLC increased its position in shares of Affimed by 34.0% during the fourth quarter. Intellectus Partners LLC now owns 126,414 shares of the biopharmaceutical company’s stock worth $150,000 after acquiring an additional 32,053 shares during the period. Jane Street Group LLC bought a new stake in shares of Affimed during the third quarter valued at approximately $44,000. Point72 Asset Management L.P. boosted its holdings in shares of Affimed by 4.6% in the third quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock valued at $1,152,000 after purchasing an additional 15,108 shares during the period. Finally, FMR LLC grew its stake in Affimed by 30.0% in the third quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock worth $59,000 after purchasing an additional 4,086 shares in the last quarter. Hedge funds and other institutional investors own 30.82% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Affimed in a research note on Tuesday, December 10th. Wells Fargo & Company lowered their price target on Affimed from $20.00 to $15.00 and set an “overweight” rating for the company in a research report on Thursday, December 12th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $13.50.

Affimed Stock Performance

AFMD opened at $0.72 on Tuesday. The company has a quick ratio of 1.93, a current ratio of 1.93 and a debt-to-equity ratio of 0.13. The stock’s 50 day moving average price is $0.98 and its 200-day moving average price is $2.06. Affimed has a one year low of $0.72 and a one year high of $8.95.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.